Table 1. Features of the studies included in the systemic review.
Study design | First author | Year | Country | NOX isoforms | Specimens | Data entry format |
---|---|---|---|---|---|---|
Level of NOX expression or activity | Morre J | 1997 | USA | NOX activity | Human lung tissue | Mean/SD/N |
Ilonen I | 2009 | Finland | NOX activity | Human lung tissue | N/P value | |
Luxen S | 2008 | USA | DUOX1/2 mRNA | Human lung tissue | N/P value | |
Zhang CX* | 2014 | China | NOX4 protein | Human lung tissue | N/P value | |
Metastatic lung cancer incidence | Kelkka T | 2013 | Italy | NOX2 Knockout | Mice | Rate/N |
Zhang B | 2013 | China | NOX4 siRNA | Mice | Rate/N | |
Zhang CX* | 2014 | China | NOX4 overExp | Mice | Rate/N | |
NOX level and cancer invasion | Boudreau HE | 2014 | USA | NOX4 induction | Cancer cell line | Mean/SD/N |
Vaid M | 2014 | USA | NOX inhibitor, DPI | A549 cells | N/P value | |
Liu XY | 2015 | China | DPI, NOX1-siRNA | Primary NSCLC | N/P value | |
Yan S | 2015 | China | NOX inhibitor, DPI | Primary NSCLC | Mean/SD/N | |
A549 cells | N/P value | |||||
95D cells | N/P value |
*, Zhang CX did both experiments. NOX, NADPH oxidase; SD, standard deviation; DPI, diphenyleneiodonium, NOX inhibitor.